TrialClinical cancer research : an official journal of the American Association for Cancer Research2010

Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer.

Tanya B Dorff et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.